You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
A - Regimen Name

CABO Regimen

Disease Site
Genitourinary - Renal Cell / Kidney


Regimen Category
Evidence-Informed :

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR).  Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses

For the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) that had progressed after prior vascular endothelial growth factor (VEGF)-targeted therapy.

B - Drug Regimen

cabozantinib (tablet)
60 mg PO Daily
(This drug is not currently publicly funded for this regimen and intent)

Cabozantinib tablets and capsules are not interchangeable.

back to top
C - Cycle Frequency


Until disease progression or unacceptable toxicity

D - Premedication and Supportive Measures

Antiemetic Regimen:

Low – No routine prophylaxis; PRN recommended

Other Supportive Care:

Also refer to CCO Antiemetic Recommendations.

E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated.

Prior to initiating cabozantinib therapy:

  • Blood pressure should be well-controlled.

  • Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected.

  • Optimal control of thyroid function is recommended.

Hold treatment for at least 28 days prior to scheduled surgery, including dental surgery; resume based on clinical judgment of adequate wound healing.

Dosage with toxicity

Dose Levels


Dose Level Cabozantinib (Tablet) Dose (mg/day)
0 60
-1 40
-2* 20
-3 Discontinue

*If previously receiving 20 mg daily, restart at 20 mg if tolerated. Otherwise, discontinue.

Toxicity Severity


Related hematologic/ non-hematologic/ organ toxicity Intolerable grade 2 and cannot be adequately managed Hold*; consider restart at 1 dose level ↓

Grade 3

Hold*; restart at 1 dose level ↓
Grade 4

Hold*; restart at 1 dose level ↓ 



Unmanageable fistula or GI perforation Any Discontinue
Severe hemorrhage
Arterial thromboembolic event (e.g. MI, cerebral infarction)
Torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia
Hypertensive crisis, severe uncontrolled hypertension despite optimal therapy
Nephrotic syndrome
Reversible posterior leukoencephalopathy syndrome (or PRES)
Wound healing complications requiring medical intervention

*Restart if toxicity resolved to ≤ grade 1 or baseline. Discontinue if toxicity does not resolve after 6 weeks.

Hepatic Impairment

Liver Impairment Cabozantinib (Tablet) Starting Dose (mg/day)
Mild or moderate (Child-Pugh classes A and B) 40 mg
Severe (Child-Pugh class C) Not recommended (has not been studied)



Renal Impairment

Renal Impairment Cabozantinib (Tablet) Dose (mg/day)
Mild or moderate (eGFR ≥ 30mL/min) No dosage adjustment required
Severe (eGFR <29 mL/min) Not recommended (has not been studied)


Dosage in the Elderly

No dosage adjustment is required. There were no overall differences in safety or efficacy between patients aged 65 or older and younger patients.


Dosage based on Ethnicity:

There were no overall differences in PK based on race.


F - Adverse Effects

Refer to cabozantinib (tablet) drug monograph(s) for additional details of adverse effects

Very common (≥ 50%)

Common (25-49%)

Less common (10-24%)

Uncommon (< 10%),

but may be severe or life-threatening

  • ↑ LFTs (may be severe)
  • Diarrhea (may be severe)
  • Fatigue
  • Nausea, vomiting
  • Abnormal electrolyte(s)
  • Anorexia, weight loss
  • Palmar-plantar erythrodysesthesia syndrome (PPES)
  • Hypertension (may be severe)
  • ↓ albumin
  • Myelosuppression
  • Constipation
  • Dysgeusia
  • Abdominal pain
  • Rash / dry skin
  • Mucositis
  • Hypothyroidism
  • Dysphonia
  • Cough, dyspnea
  • Musculoskeletal pain
  • Dyspepsia
  • Proteinuria
  • Dizziness
  • Headache
  • Arterial / venous thromboembolism
  • QT prolongation
  • Hemorrhage
  • Wound complication 
  • Gastrointestinal GI fistula
  • GI perforation
  • Cholestasis
  • Pancreatitis
  • Osteonecrosis of jaw
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
  • Syncope
  • Pleural effusion
G - Interactions

Refer to cabozantinib (tablet) drug monograph(s) for additional details

  • Cabozantinib is primarily metabolized by CYP3A4 and is susceptible to inhibitors and inducers of this isoenzyme. Avoid co-administration with strong CYP3A4 inducers and consider alternatives to strong CYP3A4 inhibitors.

  • Avoid co-administration to the extent possible with QTc interval-prolonging drugs.

H - Drug Administration and Special Precautions

Refer to cabozantinib (tablet) drug monograph(s) for additional details


  • Oral self-administration; drug available by outpatient prescription.

  • Tablets should be swallowed whole, not chewed or crushed.

  • Tablets should be administered on an empty stomach (no food for at least 2 hours before and 1 hour after taking a dose).

  • Avoid grapefruit, starfruit, Seville oranges, their juices or products during treatment.

  • If a dose is missed, additional dose should not be taken within 12 hours of the next dose.

  • Cabozantinib should be stored between 15oC to 25oC


  • Patients who have a hypersensitivity to this drug or any of its components


Other Warnings/Precautions:

  • Patients with a history of severe bleeding should be evaluated carefully before starting treatment. Do not give cabozantinib to patients with or at risk for severe hemorrhage.

  • Use cabozantinib with caution in patients at risk for, or who have a history of:

    • venous and/or arterial thromboembolism

    • hypertension

    • inflammatory bowel disease, tumour infiltration in the GI tract, or complications from prior GI surgery (particularly when associated with delayed or incomplete healing)

    • severe bleeding

    • low heart rate at baseline (< 60 beats per minute).

    • Syncope/arrhythmia, QT prolongation, sick sinus syndrome, sinoatrial block, atrioventricular (AV) block, ischemic heart disease, or congestive heart failure.

  • Use caution when driving or operating machinery as cabozantinib may cause fatigues, dizziness and weakness.


Pregnancy and lactation:

  • Cabozantinib is not recommended for use in pregnancy. At least 2 forms of adequate contraception (i.e. oral contraceptives and barrier method) should be used by both sexes during treatment, and for at least 4 months after the last dose.

  • Breastfeeding is not recommended during treatment and for 4 months after the last dose.

  • Fertility effects: Probably.  Documented in animals


I - Recommended Clinical Monitoring

Recommended Clinical Monitoring

  • ECG, heart rate and blood pressure; Baseline and as clinically indicated

  • Electrolytes, including calcium, potassium and magnesium; Baseline and as clinically indicated, especially in patients at risk of severe arrhythmias

  • Liver function tests; Baseline and as clinically indicated

  • Renal function tests; Baseline and as clinically indicated

  • Thyroid function tests; Baseline and as clinically indicated

  • Clinical toxicity assessment for GI effects (including perforations, fistulas),  bleeding, skin effects including PPES, respiratory and neurologic effects, thromboembolism, proteinuria, pancreatitis, osteonecrosis of the jaw and wound healing complications; At each visit

  • Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version

Suggested Clinical Monitoring

  • Blood glucose and lipid profile; Baseline and as clinically indicated

  • INR for patients receiving warfarin; Baseline and as clinically indicated

back to top
K - References

Cabozantinib drug monograph, Cancer Care Ontario.

Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23.

EPAR - Product Information: CABOMETYX™ (cabozantinib tablets). Ipsen Pharma, September 2018.

back to top
M - Disclaimer

Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph.  Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.